Nemus Bioscience Announces Advancement of Analgesic Program Utilizing NB2111, an Analogue of Cannabidiol; Approaches Pain Management with a "Continuum of Care" Strategy

COSTA MESA, CA / ACCESSWIRE / January 31, 2017 / NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that the company has signed a research agreement with the University of Mississippi (UM) to further explore the analgesic and abuse-deterrent properties of NB2111, a unique analogue of cannabidiol (CBD). We expect that these planned in vivo studies will serve to complement and expand upon early data that showed NB2111 provided dose-dependent analgesia comparable to opioids in animals exposed to noxious stimuli. NB2111 also exhibited anti-addictive activity against opioids in a validated animal model of abuse liability.

Brian Murphy, M.D., M.B.A., Nemus CEO and Chief Medical Officer, noted, "The global need for effective analgesics continues to grow with aging populations and the attendant conditions associated with diseases of old age. With research indicating a global pain management market potentially growing to $83 billion by 2024 (Transparency Market Research, 2016), Nemus plans to utilize its portfolio of cannabinoid-based therapies to develop a continuum of care for patients experiencing acute or chronic pain, as well as helping patients who may have developed an addiction to opioids convert to cannabinoid-class compounds that we believe offer analgesic coverage without the associated serious adverse safety profile associated with long-term opioid use."

"According to the Centers for Disease Control (CDC), an average of 78 opioid-related overdose deaths occur each day in the United States while 650,000 opioid prescriptions are dispensed," commented Dr. Kenneth J. Sufka, professor of Psychology and Pharmacology and Research Professor with the National Center for Natural Products Research at UM. "The opioid epidemic has reached extreme proportions and we feel having a safer yet effective alternative is vital to both national and global health. We believe these compounds will have utility in managing a spectrum of pain conditions, from the quality-of-life debilitating pain associated with fibromyalgia to intense post-surgical pain. Our team looks forward to working with Nemus to explore a variety of treatment options in anticipation of future human studies."

"The company is happy to work with Professor Sufka, a recipient of the 2014 CASE-Carnegie Award as one of the pre-eminent educator-researchers in the country," stated Dr. Murphy. "We expect to formally present this data at an upcoming peer-reviewed scientific meeting. Nemus plans to examine developmental partnering opportunities with companies who may already have a presence in this therapeutic area but are looking to expand their portfolio into cannabinoids and/or companies developing novel delivery systems, especially those that permit bypassing first-pass metabolism in the liver."


This press release contains forward-looking statements, including statements about the studies relating to and the potential benefits of NB2111, as well as the timing of our near term, intermediate term, and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "expects," "plans," "believes," "can," "could," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.


The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting potential adverse events. NEMUS's strategy is to explore the use of natural and synthetic compounds, alone or in combination with partners. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit


NEMUS Investor Relations
PCG Advisory Group 
Adam Holdsworth
Phone: 646-862-4607

NEMUS Media Relations
Janet Vasquez
JV Public Relations
Phone: 212.645.5498

SOURCE: NEMUS Bioscience, Inc.

To read more Press Release articles, click here.